Twist Bioscience Corporation Q4 2026 Earnings Call Summary

Twist Bioscience reported positive adjusted EBITDA in Q4 2026, with revenue growth driven by a 175% YoY increase in AI drug discovery. The company expects $550M-$560M revenue in 2027, with $100M from AI drug discovery. It plans $150M in CapEx over two years to support future growth. Management highlighted structural advantages and strategic initiatives in AI and nucleic acid therapeutics.

Original reporting
Published Nov 12, 2026, 10:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 10:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Twist Bioscience Corporation Q4 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$TWSTBullishHigh
01

Why it matters

The earnings call disclosed positive EBITDA, a sizable equity raise, and FY2027 revenue guidance, all of which were not previously public.

02

Market read

New guidance and capital raise provide fresh material for traders; the stock may react positively in after‑hours trading.

03

What to watch

Potential dilution from the $425 M equity raise and execution risk of scaling new capacity.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Twist Bioscience is a synthetic DNA manufacturer leveraging a silicon‑based platform for AI‑enabled drug discovery and nucleic‑acid therapeutics.

Company-level read

Ticker impact

$TWSTBullishHigh confidence
Context

Twist Bioscience reported positive adjusted EBITDA and raised $425 million, while guiding FY2027 revenue to $550‑$560 million.

Expected impact

likely upward pressure as investors price in strong guidance and fresh capital.

Evidence & confidence

First disclosure of FY2027 revenue range and sizable equity raise provides new material information.

Market effects

AI‑driven biotech and synthetic DNA platforms may see increased investor interest.

U.S. biotech sector could receive a modest boost.

Limited to biotech investors; no broad market effect.

Counterpoint

Guidance may be overly optimistic given capital intensity and margin headwinds.

Key entities

  • Twist Bioscience

    Synthetic DNA manufacturer (ticker TWST).

Related articles

$TWSTHighAI 8/10

Canaccord cuts Twist Bioscience stock price target on lower revenue outlook

Canaccord reduced Twist Bioscience's (TWST) price target to $150 from $205, citing lower long-term revenue estimates. The company's Q4 results beat expectations, with revenue up 28% YoY to $126.6M. Twist provided fiscal 2027 guidance ahead of consensus but expects slower AI-enabled drug discovery revenue growth. Jefferies also lowered its target to $125, maintaining a Hold rating. TWST shares are down in premarket trading.

$TWSTMedAI 8/10

Twist Bioscience Q4 Earnings Call Highlights

Twist Bioscience reported shipping 401,000 genes in Q4 and 1.3 million for the year. AI drug discovery revenue rose 175% to $59.1M. The company plans to expand capacity with 16 DNA writers and invest $150M in capital expenditures. Twist expects fiscal 2027 revenue of $130M-$132M in Q1 and positive adjusted EBITDA.

$TWSTMedAI 8/10

Twist Bioscience earnings analysis: questions answered and next catalysts

Twist Bioscience (TWST) reported FY2026 Q4 earnings on Nov 12, 2026, beating EPS and revenue estimates. Despite this, shares fell 7.90% to $112.91. Revenue grew 28% YoY to $126.6M, and the company achieved positive adjusted EBITDA of $2.2M. Management provided FY2027 guidance of $550M–$560M in revenue, above consensus. Concerns include valuation, capital intensity, and reliance on AI drug discovery orders. Next catalysts include Q1 FY2027 results and AI updates.

$TWSTMed

Twist Bioscience (TWST) Q4 2026 Earnings Call Transcript

Twist Bioscience reported Q4 2026 revenue of $126.6M, up 28% YoY, and full-year revenue of $460M, exceeding guidance. Adjusted EBITDA turned positive at $2.2M. The company highlighted growth in AI drug discovery, with revenue up 175% YoY, and expanded manufacturing capacity to meet demand. Twist's platform enables custom DNA manufacturing at scale, serving healthcare and research industries.